Company profile
GERON CORP
NASDAQ:GERNBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| RYTELO | approved | $0.3MQ1 2024 | 7 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04576156 | phase3 | active_not_recruiting | 2021-04-12 | 2028-06-30 | Geron Corporation | A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment |
| NCT00732056 | phase1 | completed | 2008-07-01 | 2011-09-01 | Geron Corporation | A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer |
| NCT05371964 | phase1 | active_not_recruiting | 2022-05-04 | 2027-02-01 | Geron Corporation | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis |
| NCT01731951 | phase2 | completed | 2012-10-29 | 2018-05-24 | Geron Corporation | Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis |
| NCT01137968 | phase2 | completed | 2010-05-01 | 2013-09-01 | Geron Corporation | Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC) |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 217779 | 2024-06-06 | NDA | GERON CORP | |||||
Loading… | ||||||||